Bluebird bio announced that it has commenced an underwritten public offering of 20M shares of its common stock. Goldman Sachs & Co. and J.P. Morgan Securities are acting as joint book running managers for the offering. Bluebird intends to use the net proceeds of the offering (i) to support commercialization and manufacturing for its two approved gene therapies, ZYNTEGLO and SKYSONA; (ii) to accelerate future commercialization activities for its gene therapy candidate, lovotibeglogene autotemcel (lovo-cel) for sickle cell disease, if approved; and (iii) to fund working capital and other general corporate purposes.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BLUE:
- Bluebird Bio to sell second Zynteglo PRV for $95M
- Bluebird Bio appoints Joseph Vittiglio, JD, chief business and legal officer
- Bluebird Bio completes sale pf PRV to Argenx
- FDA removing lovo-cel partial hold a positive for Bluebird, says Morgan Stanley
- Bluebird Bio reports FDA lifts clinical hold on lovotibeglogene autotemcel study
